Krystal Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	225.03	204.83	89.16	10.93	-139.98	-69.57
Depreciation & Amortization	6.64	6.55	6.71	5.91	3.39	2.77
Stock-Based Compensation	54.65	54.51	49.13	39.93	33.23	15.32
Other Adjustments	-5.4	-28.61	-7.12	-107.06	0.13	1.04
Change in Receivables	-23.55	-22.12	-62.71	-42.04	-	-
Changes in Inventories	-5.13	-6.29	-11.91	-4.48	-	-
Changes in Accounts Payable	0.94	0.83	1.01	-0.1	-1.25	0.71
Changes in Accrued Expenses	11.82	4.12	67.47	10.54	5.17	2.71
Changes in Other Operating Activities	-0.52	-12.96	-8.32	-2.44	-1.26	-0.91
Operating Cash Flow	250.28	200.87	123.42	-88.8	-100.57	-47.94
Operating Cash Flow Growth	80.70%	62.75%	-	-	-	-
Capital Expenditures	-12.9	-11.95	-4.24	-11.8	-52.98	-68.34
Sale of Property, Plant & Equipment	-0.44	-	0.44	-	-	-
Proceeds from Sale of Intangible Assets	-	-	-	100	-	-
Purchases of Investments	-444.77	-422.54	-457.74	-508.78	-318.78	-190.46
Proceeds from Sale of Investments	390.43	375.64	298.54	503.21	257.68	32.03
Investing Cash Flow	-67.23	-58.42	-163.44	82.64	-114.08	-226.77
Issuance of Common Stock	27.7	22.66	32.4	203.5	36	355.65
Repurchase of Common Stock	-16.99	-13.96	-5.39	-0.75	-0.65	-
Net Common Stock Issued (Repurchased)	10.71	8.71	27.01	202.75	35.35	355.65
Other Financing Activities	-	-	-	-	-	-7.96
Financing Cash Flow	10.71	8.71	27.01	202.75	35.35	347.69
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-1.22	0.29	-0.46	-0.16	-0.04	-
Net Cash Flow	192.54	151.44	-13.46	196.43	-179.35	72.98
Free Cash Flow	237.38	188.91	119.18	-100.6	-153.55	-116.27
Free Cash Flow Growth	25.66%	58.51%	-	-	-	-
FCF Margin	56.88%	48.55%	41.02%	-198.43%	-	-
Free Cash Flow Per Share	7.89	6.31	4.01	-3.63	-6.02	-5.24
Levered Free Cash Flow	225.89	185.14	139.88	8.56	-186.91	-132.63
Unlevered Free Cash Flow	194.76	154.68	112.2	-95.29	-192.13	-131.34

SEC Filings: 10-K · 10-Q